BioCentury | Dec 21, 2009
Company News

Epix, Nanotherapeutics, Oscient deal

...Nanotherapeutics acquired Oscient's Ramoplanin for $500,000 in bankruptcy proceedings. The macrocyclic depsipeptide inhibitor of peptidoglycan biosynthesis...
BioCentury | Aug 20, 2009
Distillery Techniques

Technology: Drug platforms

...of a ramoplanin dimer could aid the design of antibacterial therapies. The antibiotic activity of ramoplanin...
...showed that the N-acyl chain of ramoplanin is essential for its antibiotic activity and helps ramoplanin...
...steps could include using the crystal structure in the rational design of new ramoplanin analogs. Ramoplanin...
BioCentury | Aug 20, 2009
Distillery Techniques

Approach

...of a ramoplanin dimer could aid the design of antibacterial therapies. The antibiotic activity of ramoplanin...
...showed that the N-acyl chain of ramoplanin is essential for its antibiotic activity and helps ramoplanin...
...steps could include using the crystal structure in the rational design of new ramoplanin analogs. Ramoplanin...
BioCentury | Jan 7, 2008
Finance

Late stage milestones

...Optimer (NASDAQ:OPTR) OPT-80 (difimicin) Clostridium difficile-associated diarrhea (CDAD) Ph III data 2008 Oscient (NASDAQ:OSCI)/Pfizer (NYSE:PFE) Ramoplanin...
BioCentury | May 15, 2006
Clinical News

Ramoplanin: Phase III start

...Ramoplanin from Pfizer Inc. (PFE, New York, N.Y.). Oscient Pharmaceuticals Corp. (OSCI), Waltham, Mass. Product: Ramoplanin...
BioCentury | May 15, 2006
Clinical News

Ramoplanin: Phase III start

...Ramoplanin from Pfizer Inc. (PFE, New York, N.Y.). Oscient Pharmaceuticals Corp. (OSCI), Waltham, Mass. Product: Ramoplanin...
BioCentury | Feb 13, 2006
Company News

Oscient, Pfizer deal

...OSCI acquired expanded rights to ramoplanin from PFE subsidiary Vicuron Pharmaceuticals Inc. OSCI, which already had...
BioCentury | Feb 9, 2006
Company News

Oscient gains worldwide ramoplanin rights

...OSCI acquired expanded rights to ramoplanin from Pfizer (PFE) subsidiary Vicuron . OSCI, which already had...
BioCentury | Jan 2, 2006
Clinical News

Ramoplanin regulatory update

...Phase III trials in about 490 patients each. Patients will receive either 200 mg twice-daily Ramoplanin...
...days. The primary endpoint will be the response rate at the end of the therapy. Ramoplanin...
...peptidoglycan biosynthesis. Oscient Pharmaceuticals Corp. (OSCI), Waltham, Mass. Pfizer Inc. (PFE), New York, N.Y. Product: Ramoplanin...
BioCentury | Nov 15, 2004
Clinical News

Ramoplanin: Delayed Phase III

...submitted an SPA to FDA. The trial was previously reported to start by year end. Ramoplanin...
...the Phase II trial (see BioCentury, Aug. 16). Oscient Pharmaceuticals Corp. (OSCI), Waltham, Mass. Product: Ramoplanin...
Items per page:
1 - 10 of 72